Coherus Biosciences Inc. (CHRS)
Coherus Oncology: Setting Up For Important Readouts In Mid-2026
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology Q1 Earnings Call Highlights
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives $5.51 Consensus Target Price from Brokerages
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in a niche U.S. indication, but profitability hinges on pipeline success. Key catalysts include mid-2026 data readouts for casdozokitug and CHS-114; no major Q1 2026 milestones are expected.
Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Excellent. Great. Well, thank you, everyone, for joining us, joining our fireside chat with Coherus.
Coherus Oncology: On The Shaping Up
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited by a small patient population, so financial viability hinges on the success of novel pipeline agents like casdozokitug and CHS-114. Pipeline risks are significant, as neither IL-27 nor CCR8 targeting has shown efficacy in cancer yet, and early-stage biotech projects face high attrition rates.
